Associate Editor, Ophthalmology Times
Aurion Biotech completes dosing of all subjects in Phase 1/2 CLARA trial
May 1st 2024The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction.
Read More
Oculogenex founder talks about collaboration with NASA and ISS on experiment in macular degeneration
April 11th 2024Hema Ramkumar, an ophthalmologist and founder of Oculogenex, sat down with David Hutton of Ophthalmology Times to discuss their connection with NASA and their experiment on macular degeneration-treated mice in space.
Read More
Regeneron announces publication of one-year results from PULSAR and PHOTON trials
March 8th 2024Results show Eylea HD extended dosing regimens were non-inferior to aflibercept 2 mg injection (Eylea) for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
Read More
Importance of early screening for diabetic retinopathy and other diagnostic options
March 8th 2024John Bertrand, CEO of Digital Diagnostics sits down with Managing Editor David Hutton of Ophthalmology Times to talk about the importance of early screening for diabetic retinopathy as well as other diagnostic options for National Save Your Vision month.
Read More
TL-925 is a first in class, topical Bruton’s tyrosine kinase (BTK) inhibitor that prevents mast cell activation and degranulation, and also blocks the cytokine-driven inflammatory response, and restores lacrimal unit homeostasis, offering the potential for disease modification
Read More